Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3574868 | 0.81 | KDM4E (0.47) | PDE10AHTR2BTAAR1USP30JAK2 | |
| SCHEMBL24463619 | 0.80 | CNR2 (0.46) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL5851500 | 0.76 | TAAR1 (0.60) | PDE10AHTR2BTAAR1TLR7APOBEC3A | |
| SCHEMBL24463602 | 0.75 | ALOX15 (0.40) | PDE10ATLR7MCHR1 | |
| SCHEMBL3566734 | 0.75 | ALDH1A1 (0.54) | APOBEC3AAPOBEC3G | |
| SCHEMBL17561688 | 0.74 | KDM4E (0.55) | — | |
| SCHEMBL25678221 | 0.74 | ALDH1A1 (0.53) | PDE10ATAAR1USP30TLR7JAK2 | |
| SCHEMBL25680318 | 0.74 | TLR7 (0.47) | PDE10AHTR2BTAAR1USP30TLR7 | |
| SCHEMBL10268288 | 0.73 | HTR3E (0.45) | PDE10AHTR2BMCHR1 | |
| SCHEMBL24463198 | 0.73 | CLK4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057045-A | Fibroblast growth factor receptor kinase inhibitors | 金耐特生物制药公司 | 2023-05-02 | — | — | CN | disclosed |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | KINNATE BIOPHARMA INC. (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | PDE10A 3103/4885HTR2B 4216/4885TAAR1 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.